Clinical trial
A Randomised, Double-blind, Placebo-controlled, Multi-national, Phase IIIb Study to Assess the Sustained Clinical Effect and Safety of Sublingual Immunotherapy Administered as Birch Pollen Extract Solution at a Dose of 300 IR Once Daily to Patients Suffering From Birch Pollen-induced Rhinoconjunctivitis
NCT01731249 is registered in ClinicalTrials.gov with Stallergenes Greer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Placebo-controlled, Multi-national, Phase IIIb Study to Assess the Sustained Clinical Effect and Safety of Sublingual Immunotherapy Administered as Birch Pollen Extract Solution at a Dose of 300 IR Once Daily to Patients Suffering From Birch Pollen-induced Rhinoconjunctivitis
- Lead sponsor
- Stallergenes Greer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- October 31, 2012
- Enrollment
- 574 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
allergic conjunctivitis, allergic rhinitis, hypersensitivity, seasonal allergy